somatrogon-ghla (Ngenla)

Indications

• treatment of pediatric patients >= 3 years with growth hormone deficiency

Contraindications

• acute illness, malignancy
• closed epiphysis
• Prader-Willi syndrome (obesity hypoventilation syndrome)

Dosage

• 24 mg/1.2 mL (20 mg/mL) single-patient-use prefilled pen that delivers a dose in 0.2 mg increments
• 60 mg/1.2 mL (50 mg/mL) single-patient-use prefilled pen that delivers a dose in 0.5 mg increments

Monitor

• ophthalmoscopy for intracranial hypertension
• thyroid function

Adverse effects

• >= 5%
  • injection site reactions
  • nasopharyngitis
  • headache
  • pyrexia
  • anemia
  • cough
  • vomiting
  • hypothyroidism
  • abdominal pain - consider pancreatitis
  • rash
  • oropharyngeal pain
• increased risk of malignancy
• increased risk of diabetes mellitus
• intracranial hypertension

Mechanism of action

• human growth hormone analog

More general terms

• somatotropin; growth hormone; somatropin (GH)